BTIG analyst Mark Massaro downgrades T2 Biosystems (NASDAQ:TTOO) from Buy to Neutral.
Why Is Cancer Drug Focused Monopar Therapeutics Stock Trading Higher On Tuesday?
Monopar Therapeutics surges 90% premarket with 3.94 million volume after HREC clearance for Phase 1 dosimetry trial (MNPR-101-Zr) in advanced cancers.